Abstract
No translate
No translate
No translate
No translate
Phạm Mạnh Hùng; Phạm Nhật Minh; Đỗ Phương Trọng
References
1.
1. King SB 3rd (1998) The development of interventional cardiology. J Am Coll Cardiol 31:64b–88b.
2.
2. Wierny L, Plass R, Porstmann W (1974) Long-term results in 100 consecutive patients treated by transluminal angioplasty. Radiol- ogy 112:543–548.
3.
3. Kaltenbach M (2002) Evolution of interventional cardiology in Germany. J Interv Cardiol 15:33–39.
4.
4. Simpson JB, Baim DS, Robert EW, Harrison DC (1982) A new catheter system for coronary angioplasty. Am J Cardiol 49:1216–1222
5.
5. Kaltenbach M (1984) The long wire technique - a new tech- nique for steerable balloon catheter dilatation of coronary artery stenoses. Eur Heart J 5:1004–1009.
6.
6. Bonzel T, Wollschläger H, Just H (1986) A new catheter system for the mechanical dilatation of coronary stenoses with exchangeable intracoronary catheters, fast flow of the contrast agent and improved control. Biomed Tech 31:195–200.
7.
7. Byrne RA, Stone GW, Ormiston J, Kastrati A (2017) Coronary balloon angioplasty, stents, and scaffolds. Lancet 390:781–792.
8.
8. Byrne RA, Joner M, Kastrati A (2015) Stent thrombosis and restenosis: what have we learned and where are we going? The Andreas Gruntzig Lecture ESC 2014. Eur Heart J 36:3320–3331
9.
9. Sigwart U, Puel J, Mirkovitch V, Joffre F, Kappenberger L (1987) Intravascular stents to prevent occlusion and restenosis after trans- luminal angioplasty. N Engl J Med 316:701–706
10.
10. Sigwart U (1995) Non-surgical myocardial reduction for hyper- trophic obstructive cardiomyopathy. Lancet 346:211–214.
11.
11. Serruys PW, de Jaegere P, Kiemeneij F, Macaya C, Rutsch W, Heyndrickx G et al (1994) A comparison of balloon-expanda- ble-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group. N Engl J Med 331:489–495.
12.
12. Fischman DL, Leon MB, Baim DS, Schatz RA, Savage MP, Penn I et al (1994) A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators. N Engl J Med 331:496–501.
13.
13. Schomig A, Neumann FJ, Kastrati A, Schuhlen H, Blasini R, Had- amitzky M et al (1996) A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med 334:1084–1089.
14.
14. Kastrati A, Dirschinger J, Boekstegers P, Elezi S, Schuhlen H, Pache J et al (2000) Influence of stent design on 1-year outcome after coronary stent placement: a randomized comparison of five stent types in 1,147 unselected patients. Catheter Cardiovasc Interv 50:290–297.
15.
15. Kolandaivelu K, Swaminathan R, Gibson WJ, Kolachalama VB, Nguyen-Ehrenreich KL, Giddings VL et al (2011) Stent thrombo- genicity early in high-risk interventional settings is driven by stent design and deployment and protected by polymer-drug coatings. Circulation 123:1400–1409.
16.
16. Simon C, Palmaz JC, Sprague EA (2000) Influence of topography on endothelialization of stents: clues for new designs. J Long Term Effects Med Implants 10:143–151.
17.
17. Kastrati A, Mehilli J, Dirschinger J, Dotzer F, Schuhlen H, Neu- mann FJ et al (2001) Intracoronary stenting and angiographic results: strut thickness effect on restenosis outcome (ISAR-STE- REO) trial. Circulation 103:2816–2821.
18.
18. Pache J, Kastrati A, Mehilli J, Schuhlen H, Dotzer F, Hausleiter J et al (2003) Intracoronary stenting and angiographic results: strut thickness effect on restenosis outcome (ISAR-STEREO-2) trial. J Am Coll Cardiol 41:1283–1288.
19.
19. Schulz S, Mehilli J, Schomig A, Kastrati A (2010) ISAR-a story of trials with impact on practice. Circ J 74:1771–1778.
20.
20. Palmaz JC, Benson A, Sprague EA (1999) Influence of surface topography on endothelialization of intravascular metallic mate- rial. J Vasc Interv Radiol 10:439–444.
21.
21. Nakayama Y, Nishi S, Ishibashi-Ueda H, Matsuda T (2000) Surface microarchitectural design in biomedical applications: in vivo analysis of tissue ingrowth in excimer laser-directed micropored scaffold for cardiovascular tissue engineering. J Biomed Mater Res 51:520–528.
22.
22. Dibra A, Kastrati A, Mehilli J, Pache J, von Oepen R, Dirsch- inger J et al (2005) Influence of stent surface topography on the outcomes of patients undergoing coronary stenting: a rand- omized double-blind controlled trial. Catheter Cardiovasc Interv 65:374–380.
23.
23. Morice MC, Serruys PW, Sousa JE, Fajadet J, Ban Hayashi E, Perin M et al (2002) A randomized comparison of a sirolimus- eluting stent with a standard stent for coronary revascularization. N Engl J Med 346:1773–1780.
24.
24. Stone GW, Ellis SG, Cox DA, Hermiller J, O’Shaughnessy C, Mann JT et al (2004) One-year
25.
clinical results with the slow- release, polymer-based, paclitaxel-eluting TAXUS stent: the TAXUS-IV trial. Circulation 109:1942–1947.
26.
25. Joner M, Finn AV, Farb A, Mont EK, Kolodgie FD, Ladich E et al (2006) Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol 48:193–202
27.
26. Stettler C, Wandel S, Allemann S, Kastrati A, Morice MC, Schomig A et al (2007) Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet 370:937–948
28.
27. Wessely R, Hausleiter J, Michaelis C, Jaschke B, Vogeser M, Milz S et al (2005) Inhibition of neointima formation by a novel drug- eluting stent system that allows for dose-adjustable, multiple, and on-site stent coating. Arterioscler Thromb Vasc Biol 25:748–753
29.
28. Hausleiter J, Kastrati A, Wessely R, Dibra A, Mehilli J, Schratzen- staller T et al (2005) Prevention of restenosis by a novel drug- eluting stent system with a dose-adjustable, polymer-free, on-site stent coating. Eur Heart J 26:1475–1481
30.
29. Mehilli J, Byrne RA, Wieczorek A, Iijima R, Schulz S, Bruskina O et al (2008) Randomized trial of three rapamycin-eluting stents with different coating strategies for the reduction of coronary restenosis. Eur Heart J 29:1975–1982
31.
30. Desch S, Schloma D, Mobius-Winkler S, Erbs S, Gielen S, Linke A et al (2011) Randomized comparison of a polymer-free siroli- mus-eluting stent versus a polymer-based paclitaxel-eluting stent in patients with diabetes mellitus: the LIPSIA Yukon trial. JACC Cardiovasc Interv 4:452–459
32.
31. Steigerwald K, Merl S, Kastrati A, Wieczorek A, Vorpahl M, Mannhold R et al (2009) The pre-clinical assessment of rapamy- cin-eluting, durable polymer-free stent coating concepts. Bioma- terials 30:632–637
33.
32. Byrne RA, Kastrati A, Kufner S, Massberg S, Birkmeier KA, Laugwitz KL et al (2009) Randomized, non-inferiority trial of three limus agent-eluting stents with different polymer coatings: the Intracoronary Stenting and Angiographic Results: Test Effi- cacy of 3 Limus-Eluting Stents (ISAR-TEST-4) Trial. Eur Heart J 30:2441–2449
34.
33. Kufner S, Byrne RA, Valeskini M, Schulz S, Ibrahim T, Hopp- mann P et al (2016) Five-year outcomes from a trial of three
Tác giả
Phạm Mạnh Hùng: Viện Tim mạch Việt Nam - Bệnh viện Bạch Mai;
Nguyễn Ngọc Quang: Viện Tim mạch Việt Nam - Bệnh viện Bạch Mai;
Nguyễn Quốc Thái: Viện Tim mạch Việt Nam - Bệnh viện Bạch Mai;
Phạm Nhật Minh: Viện Tim mạch Việt Nam - Bệnh viện Bạch Mai;
Files
Article Views929
Document Views0
Downloads11
Section
CHUYÊN ĐỀ
Issue
Số 84+85 , 2019
Category
TIM MẠCH CAN THIỆP
Pages
33-43
Copyright Holder
2018 Tạp chí Tim mạch học Việt Nam